Telix Strengthens Board with Additional Director Appointments
Rhea-AI Summary
Telix (ASX/NASDAQ: TLX) announced two Non-Executive Director appointments effective May 11, 2026: Maria Rivas, MD, and William (Bill) Jellison, as part of Board expansion and succession planning. The hires add U.S. public company governance, late-stage clinical and commercial leadership, and corporate finance oversight to the Board.
The company said the appointments complement a recent director addition and support Telix’s evolution as a dual-listed, global commercial-stage biopharmaceutical company.
Positive
- Board experience: Adds two U.S.-listed public company directors
- Clinical leadership: Maria Rivas brings 25+ years in late-stage clinical development and commercialization
- Financial oversight: Bill Jellison brings 30+ years in corporate finance and audit committee leadership
- Effective date: Appointments effective May 11, 2026, aiding succession planning
Negative
- None.
News Market Reaction – TLX
On the day this news was published, TLX gained 0.20%, reflecting a mild positive market reaction.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Market Reality Check
Peers on Argus
Sector scanner shows mixed peer moves: RARE -5.49% (down), XENE +2.54%, ZLAB +2.62% (up). With TLX up 1.56% and the official flag set to stock-specific, this points to company-driven dynamics rather than a coordinated biotech move.
Historical Context
| Date | Event | Sentiment | Move | Catalyst |
|---|---|---|---|---|
| Apr 06 | Earnings and pipeline | Positive | +5.9% | Q1 2026 revenue growth and guidance reaffirmation with pipeline progress. |
| Apr 01 | Board appointment | Neutral | -1.2% | Appointment of David Gill as NED as part of board expansion. |
| Mar 15 | Regulatory resubmission | Positive | -0.3% | Resubmission of NDA to FDA for TLX101-Px brain cancer imaging. |
| Mar 09 | Clinical milestone | Positive | +5.5% | ProstACT Global Phase 3 Part 1 met primary safety and dosimetry objectives. |
| Mar 01 | Investor outreach | Neutral | -2.8% | Announcement of an investor education webinar on prostate imaging. |
Recent news with clear clinical or financial positives often saw aligned upside, while governance or informational items have shown a tendency toward muted or negative reactions.
Over the last month, Telix reported strong Q1 2026 revenue growth and reaffirmed guidance, alongside advancement of its radiopharmaceutical pipeline, including ProstACT Part 1 achieving primary objectives and an NDA resubmission for TLX101-Px. Governance updates, such as adding David Gill as NED, reflect ongoing board evolution. Today’s additional NED appointments extend that governance theme, complementing the recent transition toward a broadened, U.S.-experienced board.
Market Pulse Summary
This announcement expands Telix’s board with two highly experienced Non-Executive Directors, adding U.S. public company governance, financial oversight, and clinical leadership depth, effective May 11, 2026. It follows recent board changes and strong operational updates, including revenue growth and clinical progress. Investors may monitor how this enhanced governance supports Telix’s dual-listing strategy, commercialization trajectory, and future capital allocation and audit committee decisions.
Key Terms
non-executive director financial
ned financial
s&p 100 financial
nasdaq financial
nyse financial
AI-generated analysis. Not financial advice.
MELBOURNE, Australia and INDIANAPOLIS, April 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces two additional Non-Executive Director (NED) appointments, effective May 11, 20261, as part of Board expansion and succession planning:
- Maria Rivas, MD is an experienced public company board director and S&P 100 senior pharmaceutical executive with more than 25 years’ experience in late-stage clinical development, commercialization and governance leadership. Dr. Rivas currently serves on the board of directors of The Cooper Companies, Inc. (NASDAQ: COO), a medical technology company, and also served as an independent director for Medidata from 2018-2019 until its successful merger with Dassault Systèmes.
Dr. Rivas spent over 25 years in healthcare developing and commercializing medical devices and pharmaceutical products across multiple therapeutic areas including oncology, rare diseases and neurosciences, most recently as Chief Medical Officer at Pfizer, Inc. (NYSE: PFE). She has managed global operations of several thousand data scientists, healthcare experts and field staff, and overseen the launch of multiple blockbuster medical products. Dr. Rivas holds a B.A. in Biochemistry from Brandeis University and an MD from Columbia University’s Vagelos College of Physicians and Surgeons. She completed residency training in Internal Medicine and a fellowship in Endocrinology at New York-Presbyterian Hospital.
- William (Bill) Jellison is a public company director and corporate finance leader with over 30 years’ experience, including audit committee leadership in large, regulated operating environments. He currently serves on the board of directors of Medtronic plc (NYSE: MDT), Anika Therapeutics, Inc. (NASDAQ: ANIK), Avient Corporation (NYSE: AVNT), Solenis LLC, and Young Innovations, Inc., and until recently served as a director of Masimo Corporation (NASDAQ: MASI).
During his executive career, Mr. Jellison most recently served as Vice President and CFO of Stryker Corporation, overseeing international finance, SEC reporting, mergers and acquisitions, and capital allocation. He holds a B.A. in Business Administration from Hope College.
Telix Interim Chair, Dr. Mark Nelson, commented on the appointments, “We are delighted to welcome Maria and Bill, highly accomplished Non-Executive Directors whose collective experience in U.S. public company governance, financial oversight and clinical leadership will significantly enhance the Board’s capability. Along with the recent addition of David Gill, these appointments are well aligned with Telix’s evolution as a dual-listed, global, commercial stage biopharmaceutical company.”
About Telix Pharmaceuticals Limited
Telix is a global biopharmaceutical company focused on the development and commercialization of radiopharmaceuticals with the goal of addressing significant unmet medical need in oncology and rare diseases. Telix is headquartered in Melbourne (Australia) with international operations in the United States, United Kingdom, Brazil, Canada, Europe (Belgium and Switzerland) and Japan. Telix is listed on the Australian Securities Exchange (ASX: TLX) and the Nasdaq Global Select Market (NASDAQ: TLX).
Visit www.telixpharma.com for further information about Telix, including details of the latest share price, ASX and U.S. Securities and Exchange Commission (SEC) filings, investor and analyst presentations, news releases, event details and other publications that may be of interest. You can also follow Telix on LinkedIn, X and Facebook.
| Telix Investor Relations (Global) Ms. Kyahn Williamson SVP Investor Relations and Corporate Communications kyahn.williamson@telixpharma.com | Telix Investor Relations (Australia) Ms. Charlene Jaw Associate Director Investor Relations charlene.jaw@telixpharma.com | Telix Investor Relations (U.S.) Ms. Annie Kasparian Director Investor Relations and Corporate Communications annie.kasparian@telixpharma.com |
Media Contact
Eliza Schleifstein
917.763.8106 (Mobile)
Eliza@schleifsteinpr.com
This announcement has been authorized for release by the Telix Pharmaceuticals Limited Board of Directors.
Legal Notices
Cautionary Statement Regarding Forward-Looking Statements.
You should read this announcement together with our risk factors, as disclosed in our most recently filed reports with the Australian Securities Exchange (ASX), U.S. Securities and Exchange Commission (SEC), including our Annual Report on Form 20-F filed with the SEC, or on our website.
The information contained in this announcement is not intended to be an offer for subscription, invitation or recommendation with respect to securities of Telix Pharmaceuticals Limited (Telix) in any jurisdiction, including the United States. The information and opinions contained in this announcement are subject to change without notification. To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to update or revise any information or opinions contained in this announcement, including any forward-looking statements (as referred to below), whether as a result of new information, future developments, a change in expectations or assumptions, or otherwise. No representation or warranty, express or implied, is made in relation to the accuracy or completeness of the information contained or opinions expressed in the course of this announcement.
This announcement may contain forward-looking statements, including within the meaning of the U.S. Private Securities Litigation Reform Act of 1995, that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as “may”, “expect”, “intend”, “plan”, “estimate”, “anticipate”, “believe”, “outlook”, “forecast” and “guidance”, or the negative of these words or other similar terms or expressions. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on Telix’s good-faith assumptions as to the financial, market, regulatory and other risks and considerations that exist and affect Telix’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress, completion and results of Telix’s preclinical and clinical trials, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enroll and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals for Telix’s product candidates, including TLX101-Px and TLX250-Px, manufacturing activities and product marketing activities; Telix’s sales, marketing and distribution and manufacturing capabilities and strategies; the commercialization of Telix’s product candidates, if or when they have been approved; Telix’s ability to obtain an adequate supply of raw materials at reasonable costs for its products and product candidates; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; the anticipated impact of U.S. and foreign tariffs and other macroeconomic conditions on Telix’s business, including as a result of war or other geopolitical conflicts; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements.
©2026 Telix Pharmaceuticals Limited. All rights reserved.
1 Subject to grant of Australian Director Identification numbers.
